New drug for anemia in ckd
There are several new drugs being developed or recently approved for the treatment of anemia in chronic kidney disease (CKD). Here are a few examples:
- Luspatercept (Acelex): This is a novel erythropoiesis-stimulating agent (ESA) that was approved by the FDA in 2020 for the treatment of anemia in adult patients with CKD who are not on dialysis. Luspatercept works by stimulating the production of red blood cells and has been shown to be effective in reducing the need for blood transfusions.
- Molidustat (BMY-28190): This is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed for the treatment of anemia in CKD patients. Molidustat works by increasing the production of red blood cells and has been shown to be effective in reducing the need for ESAs in clinical trials.
- Vadadustat (AKB-6548): This is an oral HIF prolyl hydroxylase inhibitor that is being developed for the treatment of anemia in CKD patients. Vadadustat works by increasing the production of red blood cells and has been shown to be effective in reducing the need for ESAs in clinical trials.
- Eryaspase (Graspa): This is a pegylated enzyme that is being developed for the treatment of anemia in CKD patients. Eryaspase works by breaking down excess red blood cells and has been shown to be effective in reducing the need for blood transfusions in clinical trials.
- CR-802 (CureVac): This is a novel mRNA-based therapy that is being developed for the treatment of anemia in CKD patients. CR-802 works by stimulating the production of red blood cells and has been shown to be effective in reducing the need for ESAs in clinical trials.
These are just a few examples of the new drugs being developed for the treatment of anemia in CKD. It's important to note that these drugs are still in the development stage and have not yet been approved by regulatory agencies for use in patients.